Latest total revenue for SCPS: $0, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2023
Trailing 12 months ending Jun 2023
As of the most recent data (June 2023), SCPS shows a total revenue of $0. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, SCPS's total revenue is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Scopus Biopharma is outperforming or lagging.
The Healthcare sector average total revenue is about $110B. Scopus Biopharma is at $0, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how SCPS stacks up against individual peers as well.
Tracking SCPS's total revenue over time shows whether Scopus Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total revenue page, Stockcircle has Scopus Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $0) with ownership activity and broader fundamentals.